Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$0.54 +2.2%	$0.56	$0.40 ▼ $1.07	$11.07M	2.2	336,345 shs	559,626 shs
BTAI BioXcel Therapeutics	$1.73 +5.5%	$1.62	$1.17 ▼ $25.12	$9.93M	-0.12	1.21 million shs	96,924 shs
GLMD Galmed Pharmaceuticals	$1.78 +6.6%	$1.42	$1.15 ▼ $23.80	$2.77M	0.51	1.31 million shs	592,315 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	+2.23%	-2.00%	+3.20%	+4.77%	-46.58%
BTAI BioXcel Therapeutics	+5.49%	-3.35%	+20.14%	-26.69%	-91.14%
GLMD Galmed Pharmaceuticals	+6.27%	+5.95%	+39.06%	-22.27%	-55.77%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	0.5443 of 5 stars	0.0	4.0	0.0	0.0	0.6	0.8	0.6
BTAI BioXcel Therapeutics	3.6666 of 5 stars	3.3	2.0	0.0	4.5	0.6	1.7	0.6
GLMD Galmed Pharmaceuticals	0.3584 of 5 stars	0.0	2.0	0.0	0.0	0.0	2.5	0.6
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	0.00	N/A	N/A	N/A
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$42.60	2,362.43% Upside
GLMD Galmed Pharmaceuticals	2.00	Hold	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLMD, PHXM, AIMD, and BTAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2025	GLMD Galmed Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
3/19/2025	BTAI BioXcel Therapeutics	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/19/2025	BTAI BioXcel Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	565.61	N/A	N/A	$1.10 per share	0.50
BTAI BioXcel Therapeutics	$2.27M	4.62	N/A	N/A	($30.01) per share	-0.06
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$9.87 per share	N/A
PHXM PHAXIAM Therapeutics	$32.66M	0.32	N/A	N/A	$7.98 per share	0.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$1.29	N/A	∞	N/A	N/A	-88.07%	-48.60%	8/4/2025 (Estimated)
BTAI BioXcel Therapeutics	-$59.60M	-$13.55	N/A	N/A	N/A	-2,163.18%	N/A	-83.80%	8/5/2025 (Estimated)
GLMD Galmed Pharmaceuticals	-$7.52M	-$16.66	N/A	∞	N/A	N/A	-32.21%	-28.59%	8/26/2025 (Estimated)
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest GLMD, PHXM, AIMD, and BTAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	GLMD Galmed Pharmaceuticals	N/A	-$0.62	N/A	-$0.62	N/A	N/A
5/12/2025	Q1 2025	AIMD Ainos	N/A	-$0.21	N/A	-$0.21	N/A	$0.11 million
5/12/2025	Q1 2025	BTAI BioXcel Therapeutics	-$2.72	-$1.50	+$1.22	-$1.50	$0.35 million	$0.17 million
3/27/2025	Q4 2024	BTAI BioXcel Therapeutics	-$4.36	-$3.57	+$0.79	-$3.57	$0.72 million	$0.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.84	2.00	1.91
BTAI BioXcel Therapeutics	N/A	1.48	1.45
GLMD Galmed Pharmaceuticals	N/A	9.02	9.02
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
BTAI BioXcel Therapeutics	30.68%
GLMD Galmed Pharmaceuticals	76.14%
PHXM PHAXIAM Therapeutics	0.40%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
BTAI BioXcel Therapeutics	21.20%
GLMD Galmed Pharmaceuticals	19.80%
PHXM PHAXIAM Therapeutics	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	20.76 million	18.61 million	Not Optionable
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
GLMD Galmed Pharmaceuticals	20	1.65 million	1.33 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data

GLMD, PHXM, AIMD, and BTAI Headlines

Recent News About These Companies

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

June 18 at 4:18 AM | finance.yahoo.com

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

June 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

June 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

May 23, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure

May 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Update on the Receivership Procedure

April 25, 2025 | finance.yahoo.com

Phaxiam Therapeutics S.A.

March 28, 2025 | wsj.com

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

March 15, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

March 6, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

March 6, 2025 | finance.yahoo.com

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

January 31, 2025 | businesswire.com

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

January 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

January 7, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

December 31, 2024 | finance.yahoo.com

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

November 27, 2024 | globenewswire.com

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

November 18, 2024 | globenewswire.com

Phaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | finanznachrichten.de

PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | globenewswire.com

PHAXIAM Therapeutics S.A. (PHXM.PA)

November 6, 2024 | finance.yahoo.com

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

November 4, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD, PHXM, AIMD, and BTAI Company Descriptions

Ainos NASDAQ:AIMD

$0.54 +0.01 (+2.23%)

As of 06/18/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

BioXcel Therapeutics NASDAQ:BTAI

$1.73 +0.09 (+5.49%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.03 (+1.79%)

As of 06/18/2025 06:11 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Galmed Pharmaceuticals NASDAQ:GLMD

$1.78 +0.11 (+6.59%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.90 +0.12 (+6.97%)

As of 06/18/2025 07:59 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 06/16/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time